Thank you for attending THSNA 2026. The virtual meeting is now closed.
Use this page to browse all contributing authors.
Presentations for Anthony KC Chan
Mim8 Prophylaxis in Adults and Adolescents with Hemophilia A: 52-Week Efficacy and Safety Outcomes from the Phase 3 FRONTIER2 Study |
Concizumab Efficacy in Patients With Hemophilia A/B Without Inhibitors from the Phase 3 explorer8 Study: A Post-hoc Sensitivity Analysis for the Intra-patient Comparison of Concizumab With Previous Prophylaxis |